212 related articles for article (PubMed ID: 34320004)
1. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19.
Briggs N; Gormally MV; Li F; Browning SL; Treggiari MM; Morrison A; Laurent-Rolle M; Deng Y; Hendrickson JE; Tormey CA; Desruisseaux MS
PLoS One; 2021; 16(7):e0254453. PubMed ID: 34320004
[TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
Alsharidah S; Ayed M; Ameen RM; Alhuraish F; Rouheldeen NA; Alshammari FR; Embaireeg A; Almelahi M; Adel M; Dawoud ME; Aljasmi MA; Alshammari N; Alsaeedi A; Al-Adsani W; Arian H; Awad H; Alenezi HA; Alzafiri A; Gouda EF; Almehanna M; Alqahtani S; Alshammari A; Askar MZ
Int J Infect Dis; 2021 Feb; 103():439-446. PubMed ID: 33285283
[TBL] [Abstract][Full Text] [Related]
4. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
[TBL] [Abstract][Full Text] [Related]
5. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
Bihariesingh-Sanchit R; Bansie R; Ramdhani N; Mangroo R; Bustamente D; Diaz E; Fung A Foek C; Thakoer I; Vreden S; Choudhry Z; van 't Wout AB; Diavatopoulos DA; Nierich AP
mBio; 2023 Apr; 14(2):e0337922. PubMed ID: 36815780
[TBL] [Abstract][Full Text] [Related]
6. Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience.
Ateş İ; Erden A; Güven SC; Gürler EK; Çağlayan A; Güçbey Ö; Apaydın H; Şahiner ES; Küçük H; Varan Ö; Omma A; Küçükşahin O
Transfus Apher Sci; 2021 Dec; 60(6):103238. PubMed ID: 34412949
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.
Yoon HA; Bartash R; Gendlina I; Rivera J; Nakouzi A; Bortz RH; Wirchnianski AS; Paroder M; Fehn K; Serrano-Rahman L; Babb R; Sarwar UN; Haslwanter D; Laudermilch E; Florez C; Dieterle ME; Jangra RK; Fels JM; Tong K; Mariano MC; Vergnolle O; Georgiev GI; Herrera NG; Malonis RJ; Quiroz JA; Morano NC; Krause GJ; Sweeney JM; Cowman K; Allen S; Annam J; Applebaum A; Barboto D; Khokhar A; Lally BJ; Lee A; Lee M; Malaviya A; Sample R; Yang XA; Li Y; Ruiz R; Thota R; Barnhill J; Goldstein DY; Uehlinger J; Garforth SJ; Almo SC; Lai JR; Gil MR; Fox AS; Chandran K; Wang T; Daily JP; Pirofski LA
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33476300
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
9. Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19.
Zhou CK; Bennett MM; Villa CH; Hammonds KP; Lu Y; Ettlinger J; Priest EL; Gottlieb RL; Davis S; Mays E; Clarke TC; Shoaibi A; Wong HL; Anderson SA; Kelly RJ
PLoS One; 2022; 17(8):e0273223. PubMed ID: 35980913
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.
Yokoyama APH; Wendel S; Bonet-Bub C; Fachini RM; Dametto APF; Blumm F; Dutra VF; Candelaria GTP; Sakashita AM; Machado RRG; Fontão-Wendel R; Hamerschlak N; Achkar R; Assunção MSC; Scuracchio P; Nudelman V; Pastore L; Pinho JRR; Ben MD; Filho RK; Marra AR; Amano MT; Kallás EG; Helito AS; de Carvalho CRR; Araujo DB; Durigon EL; Camargo AA; Rizzo LV; Reis LFL; Kutner JM
Transfusion; 2021 Aug; 61(8):2295-2306. PubMed ID: 34173248
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Convalescent Plasma for Treatment of Severe COVID-19.
De Santis GC; Oliveira LC; Garibaldi PMM; Almado CEL; Croda J; Arcanjo GGA; Oliveira ÉAF; Tonacio AC; Langhi DM; Bordin JO; Gilio RN; Palma LC; Santos EV; Haddad SK; Prado BPA; Pontelli MC; Gomes R; Miranda CH; Auxiliadora Martins M; Covas DT; Arruda E; Fonseca BAL; Calado RT
Emerg Infect Dis; 2022 Mar; 28(3):548-555. PubMed ID: 35081022
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
13. Early mortality benefit with COVID-19 convalescent plasma: a matched control study.
Shenoy AG; Hettinger AZ; Fernandez SJ; Blumenthal J; Baez V
Br J Haematol; 2021 Feb; 192(4):706-713. PubMed ID: 33482025
[TBL] [Abstract][Full Text] [Related]
14. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
Trials; 2021 May; 22(1):323. PubMed ID: 33947446
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
[TBL] [Abstract][Full Text] [Related]
16. A Multicenter, Prospective, Observational, Cohort-Controlled Study of Clinical Outcomes Following Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Therapy in Hospitalized Patients With COVID-19.
Chauhan L; Pattee J; Ford J; Thomas C; Lesteberg K; Richards E; Bernas CA; Loi M; Dumont L; Annen K; Berg M; Zirbes M; Knight V; Miller A; Jenkins TC; Bennett TD; Monkowski D; Boxer RS; Beckham JD
Clin Infect Dis; 2022 Aug; 75(1):e466-e472. PubMed ID: 34549274
[TBL] [Abstract][Full Text] [Related]
17. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of COVID convalescent plasma therapy in hospitalized moderate coronavirus disease 2019 patients.
Irawan C; Rumende CM; Sukrisman L; Pitoyo CW; Suwarto S; Susilo A; Mulansari NA; Harahap AT; Priantono D; Syafitri R; Chunaeni S; Ritchie NK
J Infect Dev Ctries; 2023 Jan; 17(1):43-51. PubMed ID: 36795929
[TBL] [Abstract][Full Text] [Related]
19. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.
Körper S; Weiss M; Zickler D; Wiesmann T; Zacharowski K; Corman VM; Grüner B; Ernst L; Spieth P; Lepper PM; Bentz M; Zinn S; Paul G; Kalbhenn J; Dollinger MM; Rosenberger P; Kirschning T; Thiele T; Appl T; Mayer B; Schmidt M; Drosten C; Wulf H; Kruse JM; Jungwirth B; Seifried E; Schrezenmeier H;
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464358
[TBL] [Abstract][Full Text] [Related]
20. Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation.
Park H; Yu C; Pirofski LA; Yoon H; Wu D; Li Y; Tarpey T; Petkova E; Antman EM; Troxel AB;
BMC Infect Dis; 2024 Jun; 24(1):639. PubMed ID: 38926676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
